Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 15/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1221236 | 0.90 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL1221719 | 0.88 | SMN1; SMN2 (0.50) | S1PR1HSD17B10KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL1219843 | 0.77 | RAB9A (0.47) | SMN1; SMN2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL541998 | 0.75 | MAPT (0.56) | KDM4ESMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL9185101 | 0.74 | PDE4D (0.43) | S1PR1HSD17B10KDM4ESMN1; SMN2RAB9A | |
| SCHEMBL31128557 | 0.72 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL9260235 | 0.72 | PDE4D (0.43) | S1PR1HSD17B10KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL1220996 | 0.70 | DRD2 (0.35) | SMN1; SMN2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL9181864 | 0.69 | PDE4D (0.43) | S1PR1HSD17B10KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL1221654 | 0.69 | L3MBTL1 (0.48) | SMN1; SMN2NPC1RAB9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110044943-A1 | Anti-Viral Compounds, Compositions, And Methods Of Use | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| WO-2010081145-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLAXOSMITHKLINE LLC (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-2178877-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GlaxoSmithKline LLC (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20100029655-A1 | Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them | LEIVERS MARTIN ROBERT | 2010-02-04 | — | — | US | disclosed |
| WO-2010006096-A1 | PROCESSES FOR THE PREPARATION OF ANTI-VIRAL COMPOUNDS AND COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-14 | — | — | WO | disclosed |
| US-20090197880-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090074717-A1 | Anti-viral compounds, compositions, and methods of use | GLAXOSMITHKLINE LLC | 2009-03-19 | — | — | US | disclosed |
| WO-2009011787-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074717-A1 | Anti-viral compounds, compositions, and methods of use | HAVCR2, SARS1, RPL35 | S1PR1 3054/4885HSD17B10 2844/4885KDM4E 3172/4885 |
| US-20110044943-A1 | Anti-Viral Compounds, Compositions, And Methods Of Use | HAVCR2, SARS1, RPL35 | S1PR1 3054/4885HSD17B10 2844/4885KDM4E 3172/4885 |
| US-20090197880-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HAVCR2, SARS1, RPL35 | S1PR1 3054/4885HSD17B10 2844/4885KDM4E 3172/4885 |
| US-20100029655-A1 | Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them | RPL35, HAVCR2, RPL5 | S1PR1 4081/4885HSD17B10 3476/4885KDM4E 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.